Document is current
Any future updates will be listed below
-
Authors
Komatsu, Jun
Cico, Alba
Poncin, Raya
Le Bohec, Maël
Morf, Jörg
Lipin, Stanislav
Graindorge, Antoine
Eckert, Hélène
Saffarian, Azadeh
Cathaly, Léa
Guérin, Frédéric
Majello, Sara
Ulveling, Damien
Vayaboury, Anaïs
Fernandez, Nicolas
Dimitrova, Dilyana
Bussell, Xavier
Fourne, Yannick
Chaumat, Pierre
André, Barbara
Baldivia, Elodie
Godet, Ulysse
Guinin, Mathieu
Moretto, Vivien
Ismail, Joy
Caille, Olivier
Roblot, Natacha
Beaupère, Carine
Liboz, Alexandrine
Guillemain, Ghislaine
Blondeau, Bertrand
Walrafen, Pierre
Edelstein, Stuart
-
Funding
Funding for this research was provided by:
Scipio bioscience
- License Information
-
More Information
Article History
Received: 13 October 2022
Accepted: 20 March 2023
First Online: 24 March 2023
Competing interests
: Authors P.W. and S.E. are founders, officers, and stockholders in Scipio bioscience, and J.K., R.P., J.M., S.L., A.G., and H.E. possess stock options. Other authors A.C., M.L.B., L.C., F.G., S.M., D.U., A.V., N.F., D.D., X.B., Y.F., P.C., B.A., E.B., U.G., M.G., V.M., J.I., O.C., N.R., C.B., A.L., G.G., and B.B. have no competing interests. Scipio bioscience owns several patent application families on the precepts (EP18733327.3), the protocol (EP 22 305 661.5) and the consumable (EP 22 305 661.5) of the RevGel-seq technology. These applications, of which the authors from Scipio bioscience are inventors, protect the inventions in numerous countries throughout the world. Subsequent patents have been filed by Scipio bioscience.
